Tchana-Sato Vincent, Dogné Jean-Michel, Lambermont Bernard, Ghuysen Alexandre, Magis David, Morimont Philippe, Hanson Julien, D'Orio Vincent, Limet Raymond, Kolh Philippe
Hemodynamic Research Center (HemoLiège), University of Liège, Liège 4000, Belgium.
Prostaglandins Other Lipid Mediat. 2005 Dec;78(1-4):82-95. doi: 10.1016/j.prostaglandins.2005.04.001. Epub 2005 Jun 20.
The aim of our study was to evaluate the effects of thromboxane A2 (TXA2) agonist, U-46619, on systemic circulatory parameters in the pigs before and after administration of a novel TXA2 receptor antagonist and synthase inhibitor (BM-573). Twelve anesthetized pigs were randomly assigned in two groups: in Ago group (n=6), the animals received six consecutive injections of U-46619 at 30 min interval, while in Anta group (n=6) they received an increasing dosage regimen of BM-573 10 min before each U-46619 injection. The effects of each dose of BM-573 on ex vivo platelet aggregation induced by arachidonic acid, collagen or ADP were also evaluated. Vascular properties such as characteristic impedance, peripheral resistance, compliance, arterial elastance were estimated using a windkessel model. Intravenous injections of 0.500 mg/ml of BM-573 and higher doses resulted in a complete inhibition of platelet aggregation induced by arachidonic acid. In the same conditions, BM-573 completely blocked the increase of arterial elastance, and stabilized both mean aortic blood pressure and mean systemic blood flow. In conclusion, BM-573 could therefore be a promising therapeutic approach in pathophysiological states where TXA2 plays a main role in the increase of vascular resistance like in pathologies such as systemic hypertension.
我们研究的目的是评估血栓素A2(TXA2)激动剂U-46619在给予新型TXA2受体拮抗剂和合成酶抑制剂(BM-573)前后对猪全身循环参数的影响。将12只麻醉猪随机分为两组:在激动剂组(n = 6)中,动物每隔30分钟连续接受6次U-46619注射,而在拮抗剂组(n = 6)中,它们在每次U-46619注射前10分钟接受递增剂量方案的BM-573。还评估了各剂量BM-573对花生四烯酸、胶原或ADP诱导的离体血小板聚集的影响。使用风箱模型估计血管特性,如特性阻抗、外周阻力、顺应性、动脉弹性。静脉注射0.500 mg/ml及更高剂量的BM-573可完全抑制花生四烯酸诱导的血小板聚集。在相同条件下,BM-573完全阻断了动脉弹性的增加,并稳定了平均主动脉血压和平均全身血流量。总之,因此在TXA2在血管阻力增加中起主要作用的病理生理状态下,如在系统性高血压等疾病中,BM-573可能是一种有前景的治疗方法。